Chiome Bioscience (TSE:4583) Beta: 0.2770 (As of Jun. 25, 2026)


TSE:4583 Chiome Bioscience Inc TSE:4583
50 GF Score
Price 円66.00
GF Value 円82.68
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Chiome Bioscience Beta?

Chiome Bioscience TSE:4583 50 Beta is 0.2770 as of Jun. 25, 2026. GuruFocus rates TSE:4583 with a GF Score™ of 50/100 and a GF Value™ of 円82.68 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Chiome Bioscience's Beta is 0.2770.


Chiome Bioscience  (TSE:4583) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Chiome Bioscience Beta Related Terms


Chiome Bioscience Beta Historical Data

* Premium members only.

The historical data trend for Chiome Bioscience's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chiome Bioscience Beta Chart

Chiome Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.12 0.90 0.45 0.49 0.53

Chiome Bioscience Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.49 0.74 0.77 0.53 0.52

TSE:4583 vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Chiome Bioscience's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chiome Bioscience Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chiome Bioscience's Beta distribution charts can be found below:

* The bar in red indicates where Chiome Bioscience's Beta falls into.


TSE:4583
50GF Score
Chiome Bioscience Inc TSE:4583
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chiome Bioscience Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.2770 mean?
Chiome Bioscience (TSE:4583) has a Beta of 0.2770 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Chiome Bioscience and its competitors.
Is Chiome Bioscience's Beta too high?
Chiome Bioscience's current Beta is 0.2770. Overall, Chiome Bioscience has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chiome Bioscience's Beta compare to VRTX and REGN?
Chiome Bioscience's Beta of 0.2770 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Chiome Bioscience and its competitors. Chiome Bioscience's current Beta is 0.2770. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chiome Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Chiome Bioscience (TSE:4583) is currently considered Modestly Undervalued. The stock's GF Value™ is 円82.68, compared to a current price of 円66.00 — trading 20.2% below its estimated fair value. The current Beta is 0.2770. Chiome Bioscience's overall GF Score™ is 50/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Chiome Bioscience (TSE:4583), the current Beta is 0.2770 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chiome Bioscience (TSE:4583) Overvalued in 2026?

Based on GuruFocus' analysis, Chiome Bioscience stock appears to be undervalued. The current stock price of 円66.00 is trading 20.2% below its estimated GF Value™ of 円82.68. GuruFocus considers Chiome Bioscience to be Modestly Undervalued.

Key valuation signals for TSE:4583:

  • Beta: 0.2770
  • GF Value™: 円82.68 vs. price of 円66.00 (20.2% below fair value)
  • GF Score™: 50/100 with 2 warning signs

No single metric tells the full story. See the TSE:4583 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Chiome Bioscience Business Description

Address 3-12-1 Honmachi, No. 6, Sumitomo Fudosan Nishi Shinjuku Building, Shibuya-ku, Tokyo, JPN, 151-0071
Chiome Bioscience Inc is engaged in the discovery and development of antibody drugs, focusing on early-stage research and initial clinical trials. The company operates through two reportable segments: the Drug Discovery segment and the Drug Discovery Support segment. The Drug Discovery segment conducts research on antibody creation for diseases with high unmet medical needs and aims to generate revenue through licensing agreements, upfront payments, milestone payments, and royalties. The Drug Discovery Support segment provides services such as antibody production and related support using proprietary antibody technologies, catering to pharmaceutical and diagnostic companies as well as academic institutions.
50GF Score

Get the complete analysis for TSE:4583

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円66.00
Price
円82.68
GF Value